New data demonstrates SonoThera’s novel, ultrasound-mediated gene delivery (UMGD) platform’s ability to noninvasively provide safe, effective gene therapy delivery to liver. Presentation focuses on ...
CAMBRIDGE, Mass. & BEIJING--(BUSINESS WIRE)--BeiGene (NASDAQ: BGNE; HKEX: 06160), a global, science-driven biotechnology company focused on developing innovative and affordable medicines to improve ...
ZUG, Switzerland and BOSTON, Dec. 09, 2024 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious ...
The company states: “Keros Therapeutics (KROS) announced that it presented additional data from its two ongoing Phase 2 clinical trials of elritercept, KER-050, one in patients with very low-, low-, ...
ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Dec. 08, 2024 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to Art. 53 LR – Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage ...
Beam Therapeutics Inc. will present additional data from phase 1/2 BEACON study, using BEAM-101 for the treatment of patients with SCD at the upcoming ASH Annual Meeting on December 7th - 10th of 2024 ...
C4 Therapeutics (CCCC) presented clinical data from the ongoing Phase 1 trial of cemsidomide, an orally bioavailable small molecule degrader of IKZF1/3, at the ASH Annual Meeting. Presentations ...
In a tight BCMA CAR-T race, Bristol Myers Squibb has delivered the drug class’s first randomized trial win in multiple myeloma. But the detailed data, recently rejected by the American Society of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback